Innovations In Clinical Neuroscience

NOV-DEC 2017

A peer-reviewed, evidence-based journal for clinicians in the field of neuroscience

Issue link: https://innovationscns.epubxp.com/i/924986

Contents of this Issue

Navigation

Page 5 of 83

6 ICNS Innovations in Clinical Neuroscience • November–December 2017 • Volume 14 • Number 11–12 THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS)—Past, Present, and Future Developments: A Compendium of Research and Perspectives IN THIS ISSUE VOL. 14, NO. 7–8 • JULY–AUGUST 2017 • INNOVATIONSCNS.COM GUEST EDITORIAL MESSAGE ..................................................................................................................................3 JOURNAL MASTHEAD ..............................................................................................................................................5 EDITORIAL ADVISORY BOARD ................................................................................................................................8 PRECURSORS TO THE PANSS: The BPRS and its Progenitors .................................................................................10 by Nina R. Schooler, PhD A DEVELOPMENTAL HISTORY OF THE POSITIVE AND NEGATIVE Syndrome Scale (PANSS) .............................12 by Stacy Liechti, PhD; Gianna Capodilupo, MA; Douglas J. Opler, MD; Mark Opler, PhD, MPH; and Lawrence H. Yang, PhD USING THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience .... 18 by Philip D. Harvey, PhD; Anzalee Khan, PhD; and Richard S. E. Keefe, PhD INSIGHT AND TREATMENT OUTCOMES IN SCHIZOPHRENIA: Post-hoc Analysis of a Long-term, Double-blind Study Comparing Lurasidone and Quetiapine XR ......................................................................................................23 by Philip D. Harvey, PhD; Cynthia O. Siu, PhD; and Antony D. Loebel, MD NEGATIVE SYMPTOM DIMENSIONS OF THE POSITIVE AND NEGATIVE Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency .......................................................................30 by Anzalee Khan, PhD; Lora Liharska, MS; Philip D. Harvey, PhD; Alexandra Atkins, PhD; Daniel Ulshen, BA; and Richard S.E. Keefe, PhD DISPARITY BETWEEN GENERAL SYMPTOM RELIEF AND REMISSION Criteria in the Positive and Negative Syndrome Scale (PANSS): A Post-treatment Bifactor Item Response Theory Model ...................................................41 by Ariana E. Anderson, PhD; Steven P. Reise, PhD; Stephen R. Marder, MD; Maxwell Mansolf, MS; Carol Han, BS; and Robert M. Bilder, PhD UNDERSTANDING ANTIPSYCHOTIC DRUG TREATMENT EFFECTS: A Novel Method to Reduce Pseudospecificity of PANSS Factors........................................................................................................................................................54 by Seth C. Hopkins, Ajay Ogirala, Antony Loebel, Kenneth S. Koblan SENSITIVIT Y OF THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) in Detecting Treatment Effects via Network Analysis .................................................................................................................................................59 by Farnaz Zamani Esfahlani, MS; Hiroki Sayama, DSc; Katherine Frost Visser, MS; and Gregory P. Strauss, PhD BRIDGING THE MEASUREMENT GAP BETWEEN RESEARCH and Clinical Care in Schizophrenia: Positive and Negative Syndrome Scale-6 (PANSS-6) and Other Assessments Based on the Simplified Negative and Positive Symptoms Interview (SNAPSI) ..................................................................................................................................68 by Søren D. Østergaard, MD, PhD; Mark G. A. Opler, PhD, MPh; and Christoph U. Correll, MD ARE SHORTER VERSIONS of the Positive and Negative Syndrome Scale (PANSS) Doable? A Critical Review .........73 by Jean-Pierre Lindenmayer, MD POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) TRAINING: Challenges, Solutions, and Future Directions ...... 77 by Mark G. A. Opler, PhD, MPH; Christian Yavorsky, PhD; and David G Daniel, MD AUTHOR GUIDELINES ............................................................................................................................................82 Follow us. PANSS S p e c i a l E d i t i o n 30 th A n n i v e r s a r y Guest Co-Editors Mark G. A. Opler, PhD, MPH —Adjunct Assistant Professor, NYU School of Medicine; Chief Research Officer, MedAvante-ProPhase New York, New York. Anzalee Khan, PhD —Senior Biostatistician, NeuroCog Trials; Psychopharmacology Research Program, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, New York Ariana Anderson, PhD —Department of Psychiatry and Biobehavioral Sciences, Department of Statistics, University of California Los Angeles, Los Angeles, California

Articles in this issue

Links on this page

Archives of this issue

view archives of Innovations In Clinical Neuroscience - NOV-DEC 2017